Delving into the Latest Updates on Suzhou Junde Biotechnology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

PI3Ks(Phosphatidylinositol 3-kinase family)	1

To evaluate the safety and tolerability of TL117 capsule combined with paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma who have failed first-line platinum-based treatment, explore the maximum tolerated dose (MTD), and determine the recommended phase II dose (RP2D); evaluate the anti-tumor efficacy; and evaluate the pharmacokinetic characteristics.

Start Date26 May 2021

Sponsor / Collaborator

Suzhou Junde Biotechnology Co., Ltd.

100 Clinical Results associated with Suzhou Junde Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Suzhou Junde Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Suzhou Junde Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Suzhou Junde Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data